{"id":"heplisav","rwe":[{"pmid":"41889877","year":"2026","title":"HEPLISAV-B Breaks Immune Tolerance and Induces HBV Control via CD4 T Cell-Dependent Mechanisms in a Chronic Hepatitis B Mouse Model.","finding":"","journal":"bioRxiv : the preprint server for biology","studyType":"Clinical Study"},{"pmid":"41819640","year":"2026","title":"A narrative review of immune-mediated adverse events in clinical trials of CpG oligonucleotide toll-like receptor 9 agonists.","finding":"","journal":"Vaccine","studyType":"Clinical Study"},{"pmid":"40981716","year":"2025","title":"Influenza vaccines for 2025-2026.","finding":"","journal":"The Medical letter on drugs and therapeutics","studyType":"Clinical Study"},{"pmid":"40932460","year":"2025","title":"Revaccination Response and Lack of Hepatitis B Reactivation After HCT for Sickle Cell Disease.","finding":"","journal":"Transplant infectious disease : an official journal of the Transplantation Society","studyType":"Clinical Study"},{"pmid":"40775743","year":"2025","title":"Optimizing hepatitis B vaccination in chronic kidney disease: a comprehensive scoping review of strategies across CKD stages, dialysis, and transplant populations.","finding":"","journal":"Renal failure","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"},{"label":"Dynavax Technologies Corporation","category":"company"}],"phase":"marketed","safety":{"commonSideEffects":[{"effect":"Injection site pain","drugRate":"39%","severity":"common","organSystem":""},{"effect":"Fatigue","drugRate":"17%","severity":"common","organSystem":""},{"effect":"Headache","drugRate":"17%","severity":"common","organSystem":""},{"effect":"Unsolicited adverse events","drugRate":"42%","severity":"common","organSystem":""}],"seriousAdverseEvents":[{"effect":"Serious adverse events (overall)","drugRate":"1.5%","severity":"serious"},{"effect":"Guillain-Barré syndrome","drugRate":"0.2%","severity":"serious"},{"effect":"Granulomatosis with polyangiitis","drugRate":"0.2%","severity":"serious"},{"effect":"Lichen planus","drugRate":"0.2%","severity":"serious"},{"effect":"Grave's disease","drugRate":"0.2%","severity":"serious"}]},"trials":[],"aliases":["Hepatitis B Vaccine (Recombinant), Adjuvanted","Hepatitis B vaccine (recombinant), adjuvanted","HEPLISAV-B"],"company":"Dynavax Technologies Corporation","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=HEPLISAV","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:26:08.754104+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:26:13.876521+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=HEPLISAV","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:26:14.335811+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Surface antigen (HBsAg) vaccine antigen","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:26:15.410854+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL4297973/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:26:15.065772+00:00"}},"allNames":["heplisav"],"offLabel":[],"synonyms":[],"timeline":[],"approvals":[],"ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"Heplisav's exact mechanism of action is not publicly disclosed, but it is believed to involve the activation of Toll-like receptor 9 (TLR9) and the subsequent stimulation of immune cells through the MyD88-dependent pathway."},"commercial":{},"references":[{"id":1,"url":"https://clinicaltrials.gov/search?intr=heplisav","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=heplisav","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-31T10:41:15.461865","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:26:16.687265+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"genericName":"heplisav","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[{"nctId":"NCT00004850","phase":"","title":"Epidemiology, Infectivity and Natural History of Hepatitis C Virus Infection","status":"COMPLETED","sponsor":"National Institutes of Health Clinical Center (CC)","startDate":"1991-03-15","conditions":["Hepatitis C","Hepatitis B"],"enrollment":805,"completionDate":""},{"nctId":"NCT07497594","phase":"NA","title":"ImPrEP LEN Brasil: Twice-Yearly Lenacapavir for HIV Prevention","status":"RECRUITING","sponsor":"Oswaldo Cruz Foundation","startDate":"2026-02-03","conditions":["Contact With or Exposure to Human Immunodeficiency Virus"],"enrollment":1500,"completionDate":"2029-09"},{"nctId":"NCT00001971","phase":"","title":"Evaluation of Patients With Liver Disease","status":"RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"1992-05-27","conditions":["Hepatitis D","Hepatitis C","Hepatitis B","Liver Disease"],"enrollment":8050,"completionDate":""},{"nctId":"NCT07491848","phase":"","title":"Oral-Periodontal Evaluation and Assessment of Oral Fluid Biomarkers in Patients With Hepatitis B+D","status":"RECRUITING","sponsor":"Research Center of Periodontal-Systemic Interactions","startDate":"2026-02-15","conditions":["HEPATITIS B CHRONIC","Hepatitis D","Periodontitis"],"enrollment":25,"completionDate":"2027-02-15"},{"nctId":"NCT00001352","phase":"","title":"Fungal Infection Susceptibility","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"1993-04-01","conditions":["Cryptococcal Infection","Cryptococcal Pneumonia","Pulmonary Cryptococcosis","Cryptococcal Meningitis","Cryptococcosis"],"enrollment":800,"completionDate":""},{"nctId":"NCT01581554","phase":"","title":"Withdrawal of Therapy After Long-Term Antiviral Treatment for Chronic Hepatitis B","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2011-05-18","conditions":["Chronic Hepatitis B e Antigen Positive","Chronic Hepatitis B e Antigen Negative"],"enrollment":15,"completionDate":""},{"nctId":"NCT06544863","phase":"","title":"Evaluation of Patient Care Support for Cirrhosis and/or Liver Transplants","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2025-03-19","conditions":["Cirrhosis"],"enrollment":3000,"completionDate":"2040-03-19"},{"nctId":"NCT03394053","phase":"","title":"The Mechanistic Biology of Primary Immunodeficiency Disorders","status":"RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2018-05-30","conditions":["Primary Immunodeficiency Disorders"],"enrollment":2500,"completionDate":"2040-12-31"},{"nctId":"NCT05551273","phase":"PHASE2","title":"Study of Oral TLR8 Agonist Selgantolimod on HBsAg in Participants With Both Chronic Hepatitis B and HIV","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2023-05-05","conditions":["Hepatitis B","HIV Infections"],"enrollment":29,"completionDate":"2026-04-29"},{"nctId":"NCT06364930","phase":"PHASE4","title":"SGLT2i to Prevent of Liver Complications in Patients With CHB and Diabetes Mellitus","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2024-03-26","conditions":["Chronic Hepatitis B"],"enrollment":412,"completionDate":"2031-03-30"},{"nctId":"NCT06357806","phase":"NA","title":"The Treatment of PD-1 Antibody Combined With Peg-IFNα in NAs-suppressed CHB Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing 302 Hospital","startDate":"2024-05-17","conditions":["Chronic Hepatitis B"],"enrollment":45,"completionDate":"2026-10-08"},{"nctId":"NCT06092333","phase":"PHASE2","title":"VIR-2218 and Peginterferon Alfa-2a for Chronic Hepatitis B","status":"RECRUITING","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2025-01-31","conditions":["Chronic Hepatitis B"],"enrollment":50,"completionDate":"2028-08-31"},{"nctId":"NCT07024641","phase":"PHASE1","title":"A Study to Assess the Safety, Tolerability, and Pharmacokinetics of GIGA-2339 in Participants With Chronic Hepatitis B Virus Infection","status":"RECRUITING","sponsor":"GigaGen, Inc.","startDate":"2024-11-13","conditions":["Hepatitis B Virus Infection"],"enrollment":48,"completionDate":"2027-09"},{"nctId":"NCT07481032","phase":"NA","title":"Effect of Fufang Biejiaruangan Combined With Antiviral Therapy on the Incidence of Hepatocellular Carcinoma in Patients With Hepatitis B-related Cirrhosis: A Multicenter, Randomized, Placebo-controlled Study","status":"NOT_YET_RECRUITING","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2026-04-01","conditions":["Cirrhosis, Liver","Hepatocellular Carcinoma (HCC)","HEPATITIS B CHRONIC"],"enrollment":1034,"completionDate":"2028-11-30"},{"nctId":"NCT07471217","phase":"PHASE1","title":"[¹⁴C] Hydronidone Mass Balance Study","status":"NOT_YET_RECRUITING","sponsor":"Beijing Continent Pharmaceutical Co, Ltd.","startDate":"2026-04-30","conditions":["Chronic Hepatitis B-related Liver Fibrosis"],"enrollment":8,"completionDate":"2026-07-30"},{"nctId":"NCT07459426","phase":"","title":"Entecavir Resistance-Associated Mutations in Chronic HBV Patients in Turkey (STREAM Study)","status":"NOT_YET_RECRUITING","sponsor":"Yaşar Bayındır, MD","startDate":"2026-03-15","conditions":["Hepatitis B, Chronic"],"enrollment":700,"completionDate":"2027-03-15"},{"nctId":"NCT07450651","phase":"","title":"Hepatic and Splenic Microcirculatory Perfusion for Ruling Out High-Risk Varices in Patients With Hepatitis B-Related Cirrhosis","status":"NOT_YET_RECRUITING","sponsor":"Beijing Friendship Hospital","startDate":"2026-02","conditions":["Hepatitis B Virus Related Cirrhosis","Portal Hypertension Related to Cirrhosis","Esophagogastric Varices"],"enrollment":150,"completionDate":"2026-10"},{"nctId":"NCT07389044","phase":"PHASE1","title":"A Study on IB-001 Dose Response and Tolerability in Healthy Adults and Those With Chronic Hepatitis B","status":"RECRUITING","sponsor":"IntegerBio","startDate":"2026-02-20","conditions":["Chronic Hepatitis B Virus Infection"],"enrollment":90,"completionDate":"2027-07-01"},{"nctId":"NCT03419481","phase":"PHASE2","title":"Pembrolizumab in Hepatocellular Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"CCTU","startDate":"2018-04-30","conditions":["HCC"],"enrollment":30,"completionDate":"2027-12-30"},{"nctId":"NCT05621304","phase":"","title":"Optimizing HBV Care Cascade Among Foreign-Born in the United States (FOCUS-HBV Study)","status":"COMPLETED","sponsor":"National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)","startDate":"2017-01-03","conditions":["Chronic Hepatitis B Virus (Hbv)"],"enrollment":274,"completionDate":"2026-02-26"},{"nctId":"NCT02932150","phase":"PHASE2","title":"Study of Tenofovir Alafenamide (TAF) in Children and Teen Participants With Chronic Hepatitis B Virus Infection","status":"RECRUITING","sponsor":"Gilead Sciences","startDate":"2016-11","conditions":["Chronic Hepatitis B"],"enrollment":150,"completionDate":"2029-10"},{"nctId":"NCT07342881","phase":"PHASE1","title":"Single Dose Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Pevifoscorvir Sodium (ALG-000184) in Participants With Renal Impairment and in Healthy Participants With Normal Renal Function","status":"RECRUITING","sponsor":"Aligos Therapeutics","startDate":"2026-02-20","conditions":["Chronic Hepatitis B Infection"],"enrollment":30,"completionDate":"2026-07-01"},{"nctId":"NCT06779058","phase":"","title":"MR Elastography for Assessing Liver Fibrosis in Chronic Hepatitis B","status":"RECRUITING","sponsor":"Shengjing Hospital","startDate":"2025-01-01","conditions":["Chronic Hepatitis B","Liver Fibrosis"],"enrollment":600,"completionDate":"2026-12-01"},{"nctId":"NCT04357600","phase":"PHASE1,PHASE2","title":"Umbilical Cord Mesenchymal Stem Cell for Liver Cirrhosis Patient Caused by Hepatitis B","status":"ENROLLING_BY_INVITATION","sponsor":"PT. Prodia Stem Cell Indonesia","startDate":"2018-05-17","conditions":["Liver Cirrhoses"],"enrollment":12,"completionDate":"2028-12-20"},{"nctId":"NCT04496882","phase":"PHASE4","title":"Chronic Hepatitis b Patients Switch to tAf After Discontinuation of Nucleoside Analogue","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2020-09-09","conditions":["Chronic Hepatitis b","Hepatitis B Reactivation"],"enrollment":260,"completionDate":"2026-12-31"},{"nctId":"NCT03866187","phase":"PHASE1,PHASE2","title":"Safety, Efficacy, Immunogenicity Study of GSK Biologicals' HBV Viral Vector and Adjuvanted Proteins Vaccine (GSK3528869A) in Adult Patients With Chronic Hepatitis B Infection","status":"TERMINATED","sponsor":"GlaxoSmithKline","startDate":"2019-03-28","conditions":["Hepatitis B, Chronic"],"enrollment":236,"completionDate":"2024-10-07"},{"nctId":"NCT04804072","phase":"NA","title":"INTEGRA: A Vanguard Study of Health Service Delivery in a Mobile Health Delivery Unit","status":"COMPLETED","sponsor":"HIV Prevention Trials Network","startDate":"2021-06-02","conditions":["HIV Infections","Drug Use","Opioid Use","Opioid-use Disorder"],"enrollment":447,"completionDate":"2024-12-17"},{"nctId":"NCT05705427","phase":"PHASE4","title":"The COMBAT HBV Feasibility Trial","status":"COMPLETED","sponsor":"University of North Carolina, Chapel Hill","startDate":"2023-08-17","conditions":["Hepatitis B","Vertical Transmission of Infectious Disease"],"enrollment":317,"completionDate":"2025-11-25"},{"nctId":"NCT07236268","phase":"","title":"Prevalence of HIV and Sexually Transmitted Infections in Migrant Communities in Slovakia","status":"COMPLETED","sponsor":"Comenius University","startDate":"2023-03-15","conditions":["STIs","HIV","Rapid Detection"],"enrollment":660,"completionDate":"2024-06-30"},{"nctId":"NCT07417553","phase":"PHASE2","title":"A Study of Hydronidone Capsules in Patients With Chronic Hepatitis B Virus-Related Liver Fibrosis","status":"NOT_YET_RECRUITING","sponsor":"Beijing Continent Pharmaceutical Co, Ltd.","startDate":"2026-03-15","conditions":["Chronic Hepatitis B-related Liver Fibrosis"],"enrollment":150,"completionDate":"2026-07-30"},{"nctId":"NCT07413549","phase":"PHASE1,PHASE2","title":"Clinical Study of Human Umbilical Cord Mesenchymal Stem Cells Injection in Patients With Decompensated Hepatitis B Cirrhosis","status":"RECRUITING","sponsor":"Beijing Tuohua Weiye Biotechnology Co., Ltd.","startDate":"2025-02-25","conditions":["Decompensated Hepatitis B Cirrhosis"],"enrollment":76,"completionDate":"2027-12-31"},{"nctId":"NCT07412236","phase":"PHASE3","title":"A Phase IIIc Clinical Study to Evaluate the Long-term Treatment of Hydronidone Capsules for Liver Fibrosis in Patients With Chronic Hepatitis B.","status":"NOT_YET_RECRUITING","sponsor":"Beijing Continent Pharmaceutical Co, Ltd.","startDate":"2026-01-30","conditions":["Liver Fibrosis","Liver Fibrosis in Chronic Hepatitis B"],"enrollment":1208,"completionDate":"2028-12-30"},{"nctId":"NCT05390424","phase":"NA","title":"Screening for Hepatitis B, Hepatitis C and AIDS Viruses Using Dried Blood Spot","status":"RECRUITING","sponsor":"University Hospital, Rouen","startDate":"2022-12-02","conditions":["Hepatitis B","Hepatitis C","AIDS"],"enrollment":500,"completionDate":"2027-01"},{"nctId":"NCT07394309","phase":"PHASE1","title":"Study of Hydroxynidone Capsules in Patients With Hepatic Impairment and Matched Healthy Controls","status":"NOT_YET_RECRUITING","sponsor":"Beijing Continent Pharmaceutical Co, Ltd.","startDate":"2026-02-15","conditions":["Liver Fibrosis"],"enrollment":30,"completionDate":"2026-10-30"},{"nctId":"NCT06507605","phase":"PHASE1","title":"Dose-Escalating Study of Pfs230D1 in Combination With R21 in Matrix-M in African Adults","status":"COMPLETED","sponsor":"Serum Institute of India Pvt. Ltd.","startDate":"2024-08-30","conditions":["Prevention of Malaria Transmission and Clinical Malaria"],"enrollment":240,"completionDate":"2026-01-24"},{"nctId":"NCT04431245","phase":"","title":"Stopping Antiviral Treatment in Chronic Hepatitis B","status":"ACTIVE_NOT_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2021-06-01","conditions":["Chronic Hepatitis b"],"enrollment":54,"completionDate":"2026-12-31"},{"nctId":"NCT05612581","phase":"PHASE1,PHASE2","title":"A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection","status":"COMPLETED","sponsor":"Vir Biotechnology, Inc.","startDate":"2023-05-10","conditions":["Hepatitis B, Chronic"],"enrollment":33,"completionDate":"2025-08-19"},{"nctId":"NCT06963710","phase":"PHASE2","title":"A Study Evaluating the Efficacy and Safety of ALG-000184 Compared With Tenofovir Disoproxil Fumarate in Untreated HBeAg-Positive and HBeAg- Negative Adult Subjects With Chronic Hepatitis B (B-SUPREME)","status":"RECRUITING","sponsor":"Aligos Therapeutics","startDate":"2025-07-15","conditions":["Chronic Hepatitis B Infection"],"enrollment":200,"completionDate":"2028-08"},{"nctId":"NCT07388979","phase":"","title":"MAGIA H3S Point of Care Test Performance for HIV, HBV, HCV, and Syphilis Screening in Pregnant Women in DR Congo","status":"NOT_YET_RECRUITING","sponsor":"Gardiens de Vies","startDate":"2026-03-01","conditions":["HIV - Human Immunodeficiency Virus","HBV (Hepatitis B Virus)","Hepatitis C Virus (HCV)","Syphilis","Mother-to-Child Transmission","Performance","Point of Care STI Testing","TREAT B"],"enrollment":7500,"completionDate":"2027-12-21"},{"nctId":"NCT05170399","phase":"PHASE4","title":"Vaccine Responses in Patients With B Cell Malignancies","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2022-09-14","conditions":["Lymphoma"],"enrollment":500,"completionDate":"2026-08-16"},{"nctId":"NCT06497504","phase":"PHASE2","title":"Study of Bepirovirsen in Participants Living With Human Immunodeficiency Virus and Chronic Hepatitis B Virus Infection (B-Focus)","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-09-17","conditions":["Hepatitis B"],"enrollment":157,"completionDate":"2027-04-22"},{"nctId":"NCT07160244","phase":"PHASE3","title":"BEATRIX: A Study to Learn About a Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Babies","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-08-25","conditions":["Healthy"],"enrollment":6000,"completionDate":"2029-03-02"},{"nctId":"NCT06082336","phase":"NA","title":"Prospective Clinical Performance Evaluation of the In-Vitro Diagnostics Medical Device MaGIA IBC for the CombIned screENing of HIV, Hepatitis B and Hepatitis C","status":"RECRUITING","sponsor":"MagIA Diagnostics","startDate":"2024-09-16","conditions":["Combined Point of Care Diagnostic of HIV, HBV and HCV"],"enrollment":252,"completionDate":"2026-11"},{"nctId":"NCT06397768","phase":"PHASE3","title":"Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-05-13","conditions":["RSV Immunization"],"enrollment":2226,"completionDate":"2025-09-18"},{"nctId":"NCT05856890","phase":"PHASE1","title":"HepB mAb19 in Individuals With Chronic Hepatitis B Infection","status":"RECRUITING","sponsor":"Rockefeller University","startDate":"2023-08-07","conditions":["Hepatitis b Virus","Hepatitis B"],"enrollment":37,"completionDate":"2028-03-30"},{"nctId":"NCT07170748","phase":"","title":"Clinical Performance Evaluation of MagIA IVD-MD Multiplex Testing (HIV/HBV/HCV/Syphilis)","status":"RECRUITING","sponsor":"MagIA Diagnostics","startDate":"2025-07-29","conditions":["Multiplex Testing of HIV, HBV, HCV and Syphilis","HIV","HBV","HCV","Syphilis","Point of Care Testing"],"enrollment":2950,"completionDate":"2026-04"},{"nctId":"NCT05147090","phase":"PHASE4","title":"Effects of Empagliflozin on Fibrosis and Cirrhosis in Chronic Hepatitis B Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"The University of Hong Kong","startDate":"2022-01-02","conditions":["Chronic Hepatitis b","NAFLD","Cirrhosis","Fibrosis, Liver","Empagliflozin","SGLT2 Inhibitors"],"enrollment":106,"completionDate":"2027-12-31"},{"nctId":"NCT06663436","phase":"PHASE2","title":"A Study on the Immune Response and Safety of a Multicomponent Shigella Vaccine in Preventing Shigellosis in Infants","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2024-11-13","conditions":["Diarrhoea"],"enrollment":200,"completionDate":"2025-10-21"},{"nctId":"NCT01651403","phase":"PHASE3","title":"Study to Evaluate the Antiviral Efficacy, Safety and Tolerability of Tenofovir Disoproxil Fumarate Versus Placebo in Pediatric Participants With Chronic Hepatitis B Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Gilead Sciences","startDate":"2012-12-06","conditions":["Chronic Hepatitis B"],"enrollment":90,"completionDate":"2027-07"},{"nctId":"NCT07200193","phase":"PHASE1,PHASE2","title":"A Phase 1/2, Open-Label, Single and Multiple Ascending Dose Study of CRMA-1001 in Adults With Chronic Hepatitis B","status":"RECRUITING","sponsor":"nChroma Bio","startDate":"2025-12-22","conditions":["Chronic Hepaititis B"],"enrollment":66,"completionDate":"2032-12-31"},{"nctId":"NCT07370207","phase":"PHASE2","title":"Phase 2 Study of AHB-137 in HBeAg Negative Chronic Hepatitis B (CHB) Participants in Asia Pacific Region","status":"NOT_YET_RECRUITING","sponsor":"AusperBio Therapeutics Inc.","startDate":"2026-02-02","conditions":["Hepatitis B, Chronic"],"enrollment":84,"completionDate":"2028-12-31"},{"nctId":"NCT06644417","phase":"PHASE2","title":"Clinical Study of TQA3605 Tablets Combined With Nucleoside (Acid) Analogs (NAs) Drugs Compared With NAs Drugs in the Treatment of Chronic Hepatitis B Virus (HBV) Infection","status":"COMPLETED","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2024-11-14","conditions":["HBV Infection With LLV"],"enrollment":122,"completionDate":"2025-12-10"},{"nctId":"NCT02750202","phase":"PHASE3","title":"Effectiveness Study of Human Papilloma Virus (HPV) Vaccines to Prevent Recurrence of Genital Warts","status":"COMPLETED","sponsor":"University of Pretoria","startDate":"2018-07-01","conditions":["Genital Warts"],"enrollment":52,"completionDate":"2025-07-31"},{"nctId":"NCT07090759","phase":"PHASE3","title":"To Evaluate the Efficacy, Safety and Population Pharmacokinetics of GST-HG141 in Patients With Chronic Hepatitis B (CHB) Who Have an Inadequate Response to Antiviral Drug Treatment","status":"RECRUITING","sponsor":"Fujian Akeylink Biotechnology Co., Ltd.","startDate":"2025-07-24","conditions":["Chronic Hepatitis b"],"enrollment":526,"completionDate":"2027-03-01"},{"nctId":"NCT05770895","phase":"PHASE1","title":"Study of HBV Therapeutic Vaccines GS-2829 and GS-6779 in Healthy Participants and Participants With Chronic Hepatitis B","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2023-04-03","conditions":["Chronic Hepatitis B"],"enrollment":83,"completionDate":"2025-01-15"},{"nctId":"NCT07364448","phase":"PHASE2","title":"A Study to Evaluate the Safety of Hydronidone Capsules in Patients With Liver Fibrosis","status":"NOT_YET_RECRUITING","sponsor":"Beijing Continent Pharmaceutical Co, Ltd.","startDate":"2026-01-30","conditions":["Chronic Hepatitis B With Hepatic Fibrosis"],"enrollment":200,"completionDate":"2026-08-30"},{"nctId":"NCT05763576","phase":"PHASE1","title":"A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7565020 in Healthy Participants and in Participants With Chronic Hepatitis B Virus Infection","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2023-04-28","conditions":["Chronic Hepatitis B"],"enrollment":60,"completionDate":"2024-12-23"},{"nctId":"NCT01298037","phase":"","title":"HBRN: Immune Regulation and Costimulation in Natural History of Chronic Hepatitis B","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2011-02-01","conditions":["Hepatitis B"],"enrollment":201,"completionDate":"2026-12-01"},{"nctId":"NCT01796457","phase":"","title":"HBRN: Immune Regulation and Costimulation in Natural History and Therapeutic Outcome of Chronic Hepatitis B","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Pennsylvania","startDate":"2013-03","conditions":["Hepatitis B"],"enrollment":40,"completionDate":"2026-12-01"},{"nctId":"NCT06786429","phase":"PHASE4","title":"Managing Hepatitis B (Hep. B) and Human Papilloma Virus (HPV) Related Cancers and Mental Health.","status":"NOT_YET_RECRUITING","sponsor":"Eunice Dube","startDate":"2026-08-30","conditions":["Hepatitis B","Human Papilloma Virus","Gall Stones (& [Calculus - Gall Bladder])","Mental Health Issue","Cancer Liver","Cancer of Cervix","Depression, Anxiety"],"enrollment":1800,"completionDate":"2031-12-30"},{"nctId":"NCT03149627","phase":"","title":"Chronic Hepatitis B Virus Clinical Epidemiology in a Representative Sample of Zambian Adults","status":"COMPLETED","sponsor":"University of Alabama at Birmingham","startDate":"2017-06-07","conditions":["HBV","Alcoholic Hepatitis","Liver Fibroses"],"enrollment":5003,"completionDate":"2018-12-19"},{"nctId":"NCT05794230","phase":"PHASE3","title":"Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-03-27","conditions":["Meningococcal Immunisation","Healthy Volunteers"],"enrollment":1528,"completionDate":"2025-11-15"},{"nctId":"NCT04294433","phase":"PHASE4","title":"Immunogenicity of 2 Versus 3 Doses of Combined Hepatitis B Vaccines in 2-18 Months Old Children","status":"COMPLETED","sponsor":"Laval University","startDate":"2018-06-11","conditions":["Hepatitis B"],"enrollment":431,"completionDate":"2023-12-30"},{"nctId":"NCT07317687","phase":"","title":"Rapid HIV, Hep C, and Syphilis Screening in a Rural Street Medicine Clinic","status":"NOT_YET_RECRUITING","sponsor":"West Virginia University","startDate":"2026-01","conditions":["HIV Testing","HEPATITIS C (HCV)","Syphilis","Hepatitis B Virus (HBV)"],"enrollment":200,"completionDate":"2028-01"},{"nctId":"NCT06647407","phase":"PHASE1,PHASE2","title":"Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-11-05","conditions":["Meningococcal Immunization","Healthy Volunteers"],"enrollment":750,"completionDate":"2027-05-17"},{"nctId":"NCT07345624","phase":"PHASE4","title":"Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3-6 Years With Immune-Tolerant Chronic Hepatitis B","status":"NOT_YET_RECRUITING","sponsor":"Qing-Lei Zeng","startDate":"2026-01-11","conditions":["Hepatitis B Virus Infection","Children","Chronic Hepatitis B"],"enrollment":80,"completionDate":"2030-12-31"},{"nctId":"NCT07345611","phase":"PHASE4","title":"Entecavir With or Without Pegylated Interferon α-2b in Children Aged 3-6 Years With Immune-Active Chronic Hepatitis B","status":"NOT_YET_RECRUITING","sponsor":"Qing-Lei Zeng","startDate":"2026-01-11","conditions":["Hepatitis B Virus Infection","Children","Chronic Hepatitis B"],"enrollment":60,"completionDate":"2030-12-31"},{"nctId":"NCT07346508","phase":"NA","title":"Project SPEED - Streamlined Protocol for Early Engagement and Delivery of HIV Prevention With Long-acting Injectable Cabotegravir: A Nurse-driven Protocol","status":"NOT_YET_RECRUITING","sponsor":"KC Care Health Center","startDate":"2026-04-01","conditions":["HIV (Human Immunodeficiency Virus)"],"enrollment":250,"completionDate":"2028-12-31"},{"nctId":"NCT07135349","phase":"PHASE2","title":"A Phase II Clinical Study of BW-20507 in Combination With PEG-IFNα for the Treatment of Hepatitis B","status":"ACTIVE_NOT_RECRUITING","sponsor":"Shanghai Argo Biopharmaceutical Co., Ltd.","startDate":"2025-09-02","conditions":["Chronic Hepatitis B"],"enrollment":209,"completionDate":"2028-05-08"},{"nctId":"NCT05561673","phase":"PHASE1","title":"A Study on the Safety and Immune Response of AS37 Together With Hepatitis B Antigen in Adults Aged 18-45 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-10-04","conditions":["Hepatitis B"],"enrollment":122,"completionDate":"2024-11-29"},{"nctId":"NCT07343778","phase":"PHASE3","title":"A Clinical Trial Evaluating the Safety of Hydronidone Capsules in Patients With Hepatic Fibrosis and Liver Cirrhosis","status":"NOT_YET_RECRUITING","sponsor":"Beijing Continent Pharmaceutical Co, Ltd.","startDate":"2026-01-20","conditions":["Chronic Hepatitis B With Hepatic Fibrosis"],"enrollment":300,"completionDate":"2026-10-30"},{"nctId":"NCT04327440","phase":"","title":"RTSS Vaccine and PBO Net Impact on Malaria Infection and Transmission in Malawi","status":"COMPLETED","sponsor":"Michigan State University","startDate":"2020-02-04","conditions":["Malaria, Malaria Vaccine, Insecticide-treated Bednets"],"enrollment":1691,"completionDate":"2021-06-30"},{"nctId":"NCT02604199","phase":"PHASE2","title":"A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-09","conditions":["Hepatitis B"],"enrollment":58,"completionDate":"2017-01"},{"nctId":"NCT02577029","phase":"PHASE2","title":"Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic Chronic Hepatitis B Virus (HBV)","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-12","conditions":["Hepatitis B","Hepatitis D"],"enrollment":79,"completionDate":"2016-12"},{"nctId":"NCT02738008","phase":"PHASE2","title":"Extension Study of the Safety and Efficacy of Multi-dose Intravenous ARC-520 in Patients With Chronic Hepatitis B (HBV) Infection","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2016-03","conditions":["Hepatitis B"],"enrollment":12,"completionDate":"2016-12"},{"nctId":"NCT02604212","phase":"PHASE2","title":"A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Positive, Chronic Hepatitis B Virus Infection","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-11","conditions":["Hepatitis B"],"enrollment":32,"completionDate":"2016-12"},{"nctId":"NCT02065336","phase":"PHASE2","title":"A Multicenter Study to Determine the Depth and Duration of Hepatitis B Surface Antigen (HBsAg) Reduction After Single or Multiple Doses of ARC-520, in Combination With Entecavir in Patients With Chronic Hepatitis B Virus (HBV) Infection","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2014-03","conditions":["Hepatitis B, Chronic"],"enrollment":58,"completionDate":"2017-01"},{"nctId":"NCT02797522","phase":"PHASE1","title":"A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chronic Hepatitis B (CHB)","status":"TERMINATED","sponsor":"Arrowhead Pharmaceuticals","startDate":"2016-06","conditions":["Hepatitis B"],"enrollment":47,"completionDate":"2016-11"},{"nctId":"NCT07328711","phase":"EARLY_PHASE1","title":"Immunomodulatory Therapy and Predictors of Clinical Cure in Chronic Hepatitis B","status":"RECRUITING","sponsor":"Peking University People's Hospital","startDate":"2026-01-01","conditions":["Chronic Hepaititis B"],"enrollment":132,"completionDate":"2028-12-31"},{"nctId":"NCT06624176","phase":"NA","title":"ShotBlocker During Intramuscular Injection Randomized Control Trial","status":"RECRUITING","sponsor":"Lauren Fortier","startDate":"2024-01-10","conditions":["Neonatal Pain"],"enrollment":200,"completionDate":"2026-08-01"},{"nctId":"NCT07320716","phase":"PHASE2","title":"Long-Term Immunogenicity of the altSonflex1-2-3 Shigella Vaccine in African Children","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-01-02","conditions":["Diarrhoea"],"enrollment":528,"completionDate":"2028-10-31"},{"nctId":"NCT06671093","phase":"PHASE1","title":"Phase 1b, Open-label Study of Tune-401 to Assess Safety, PK and PD in Adults With Chronic Hepatitis B","status":"RECRUITING","sponsor":"Tune Therapeutics, Inc.","startDate":"2024-11-29","conditions":["Chronic Hep B","Chronic Hepatitis b","Chronic Hepatitis","HBV"],"enrollment":36,"completionDate":"2028-10-30"},{"nctId":"NCT05276297","phase":"PHASE2","title":"A Study on the Safety, Efficacy and Immune Response Following Sequential Treatment With an Anti-sense Oligonucleotide Against Chronic Hepatitis B (CHB) and Chronic Hepatitis B Targeted Immunotherapy (CHB-TI) in CHB Patients Receiving Nucleos(t)Ide Analogue (NA) Therapy","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-03-22","conditions":["Hepatitis B, Chronic"],"enrollment":174,"completionDate":"2025-08-05"},{"nctId":"NCT07307586","phase":"PHASE3","title":"A Small Sample Prospective Clinical Study of Azvudine Tablets to Promote Clinical Cure in Patients With Chronic Hepatitis B","status":"RECRUITING","sponsor":"Zhigang Ren","startDate":"2025-09-01","conditions":["Chronic Hepatitis B","Azvudine"],"enrollment":120,"completionDate":"2027-12-31"},{"nctId":"NCT06993480","phase":"PHASE2","title":"A Study to Evaluate the Antiviral Activity and Immune Response of AHB-137 Injection in Participants With Chronic Hepatitis B (CHB)","status":"RECRUITING","sponsor":"Ausper Biopharma Co., Ltd.","startDate":"2025-06-18","conditions":["Chronic Hepatitis B"],"enrollment":30,"completionDate":"2026-12-01"},{"nctId":"NCT02349126","phase":"PHASE2","title":"Study of ARC-520 in Patient With Chronic Hepatitis B Virus","status":"WITHDRAWN","sponsor":"Arrowhead Pharmaceuticals","startDate":"2015-02","conditions":["Chronic Hepatitis B"],"enrollment":0,"completionDate":"2016-03"},{"nctId":"NCT06347588","phase":"","title":"Risk of Reactivation of Occult Hepatitis B in Cancer Patients During Immunotherapy.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione IRCCS Policlinico San Matteo di Pavia","startDate":"2022-06-06","conditions":["Occult Hepatitis B Infection in Cancer Patients"],"enrollment":60,"completionDate":"2026-12"},{"nctId":"NCT06901362","phase":"","title":"Seroprevalence and Vaccination Rate of Hepatitis B Virus and Varicella-zoster Virus Among Medical Students Under Immunizing Program","status":"COMPLETED","sponsor":"Thammasat University","startDate":"2025-04-01","conditions":["Healthy","Healthy Adult"],"enrollment":401,"completionDate":"2025-11-30"},{"nctId":"NCT07246889","phase":"PHASE3","title":"Study of AHB-137 in Participants With Chronic Hepatitis B (CHB) Treated With Nucleos(t)Ide Analogues (NAs)(AUSHINE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ausper Biopharma Co., Ltd.","startDate":"2025-08-12","conditions":["Chronic Hepatitis B"],"enrollment":577,"completionDate":"2027-09-01"},{"nctId":"NCT07295873","phase":"PHASE1","title":"Drug-Drug Interaction Study Between Hydronidone and Entecavir, Tenofovir Disoproxil Fumarate, Tenofovir Alafenamide, and Tenofovir Amibufenamide","status":"NOT_YET_RECRUITING","sponsor":"Beijing Continent Pharmaceutical Co, Ltd.","startDate":"2025-12-30","conditions":["Chronic Hepatitis B Liver Fibrosis","DDI (Drug-Drug Interaction)"],"enrollment":64,"completionDate":"2026-06-30"},{"nctId":"NCT05127187","phase":"NA","title":"Estimation of the Prevalence of HIV, Hepatitis C and Hepatitis B Infection Among Detainees in the Nîmes Administrative Detention Center","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2022-02-08","conditions":["HIV Infections","Hepatitis C","Hepatitis B"],"enrollment":350,"completionDate":"2022-12-07"},{"nctId":"NCT06494579","phase":"PHASE1,PHASE2","title":"Lamivudine for Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Thomas Marron","startDate":"2024-09-26","conditions":["Relapsed/Refractory Solid Tumors"],"enrollment":12,"completionDate":"2026-07-28"},{"nctId":"NCT07085377","phase":"NA","title":"Autonomous Methadone Delivery System by Nurses","status":"RECRUITING","sponsor":"Hospices Civils de Lyon","startDate":"2025-12-08","conditions":["Opioid Use Disorder (OUD)","Addictology"],"enrollment":182,"completionDate":"2028-04-08"},{"nctId":"NCT04674462","phase":"PHASE4","title":"Understanding Poor Vaccine Responses to Hepatitis B Vaccination","status":"ACTIVE_NOT_RECRUITING","sponsor":"NYU Langone Health","startDate":"2022-07-07","conditions":["Vaccine Reaction"],"enrollment":101,"completionDate":"2026-07"},{"nctId":"NCT07031219","phase":"NA","title":"HIV/HBV/HCV Triple Screening in Primary Care","status":"NOT_YET_RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2026-02-15","conditions":["HIV","HBV (Hepatitis B Virus)","HCV"],"enrollment":50,"completionDate":"2027-06"},{"nctId":"NCT07282249","phase":"PHASE3","title":"Clinical Trial to Evaluate the Efficacy and Safety of TVAX-008 Injection in the Treatment of Chronic Hepatitis B","status":"NOT_YET_RECRUITING","sponsor":"Grand Theravac Life Sciences (Nanjing) Co., Ltd.","startDate":"2025-12-31","conditions":["Chronic hepatitisB"],"enrollment":630,"completionDate":"2027-12-31"},{"nctId":"NCT05630807","phase":"PHASE3","title":"Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1)","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2022-12-07","conditions":["Chronic Hepatitis B","Hepatitis B, Chronic"],"enrollment":981,"completionDate":"2026-05-05"},{"nctId":"NCT01198860","phase":"","title":"Treatment on HBeAg Positive or HBeAg Negative in Chronic Hepatitis B","status":"APPROVED_FOR_MARKETING","sponsor":"Nguyen Thi Trieu, MD","startDate":"","conditions":["CHRONIC HEPATITIS B"],"enrollment":0,"completionDate":""},{"nctId":"NCT05630820","phase":"PHASE3","title":"Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 2)","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2022-12-06","conditions":["Chronic Hepatitis B","Hepatitis B, Chronic"],"enrollment":857,"completionDate":"2026-04-29"},{"nctId":"NCT06200545","phase":"NA","title":"Improving HIV Prevention Among Heterosexual Men Seeking STI Services in Malawi","status":"COMPLETED","sponsor":"HIV Prevention Trials Network","startDate":"2024-04-02","conditions":["HIV Infection","Sexually Transmitted Infections","Pre-exposure Prophylaxis","Systems Navigation"],"enrollment":199,"completionDate":"2025-07-28"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"chemblId":"CHEMBL4297973"},"formularyStatus":[],"_enricherVersion":"v2-openfda","developmentCodes":[],"ownershipHistory":[{"period":"","companyName":"Dynavax Technologies Corporation","relationship":"Original Developer"}],"publicationCount":78,"therapeuticAreas":["Immunology"],"biosimilarFilings":[],"originalDeveloper":"Dynavax Technologies Corporation","recentPublications":[{"date":"2026 Mar 17","pmid":"41889877","title":"HEPLISAV-B Breaks Immune Tolerance and Induces HBV Control via CD4 T Cell-Dependent Mechanisms in a Chronic Hepatitis B Mouse Model.","journal":"bioRxiv : the preprint server for biology"},{"date":"2026 Mar 11","pmid":"41819640","title":"A narrative review of immune-mediated adverse events in clinical trials of CpG oligonucleotide toll-like receptor 9 agonists.","journal":"Vaccine"},{"date":"2025 Sep 29","pmid":"40981716","title":"Influenza vaccines for 2025-2026.","journal":"The Medical letter on drugs and therapeutics"},{"date":"2025 Nov-Dec","pmid":"40932460","title":"Revaccination Response and Lack of Hepatitis B Reactivation After HCT for Sickle Cell Disease.","journal":"Transplant infectious disease : an official journal of the Transplantation Society"},{"date":"2025 Dec","pmid":"40775743","title":"Optimizing hepatitis B vaccination in chronic kidney disease: a comprehensive scoping review of strategies across CKD stages, dialysis, and transplant populations.","journal":"Renal failure"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"HEPLISAV","companyName":"Dynavax Technologies Corporation","companyId":"dynavax-technologies-corporation","modality":"Biologic","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:26:16.687265+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":false,"safety":true,"trials":true,"score":2}}